Bio-Rad expands its product range by launching two human recombinant antigens

Bio-Rad expands its product range by launching two human recombinant antigens -

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOB), a global provider of life science research and clinical diagnostic products, announced today the release of two human recombinant antigens, expansion of the company's critical raw materials portfolio for the vitro diagnostics market. These cell cultures and recombinant antigens provide customers with Bio-Rad reliable critical assay components for use in the lungs and diagnosis of ovarian cancer.

The line of Bio-Rad Critical raw materials are intermediate goods and semi-finished products which are used to re-manufacture in standards, controls, calibrators and research on the future development of 'test.

"Bio-Rad is pleased to offer an expanded range of products to better support our customers," said Conrad Maurais, Product Manager, Bio-Rad "With the introduction of
culture cell derived SCCA-1 and HE4 antigen we allow customers the opportunity to reduce their dependence on human antigens fluids and strengthen the integrity of their supply chain for these critical raw materials. "

The new antigens include:

• HE4 antigen :. used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer and endometrial

• Antigen 1 squamous cell carcinoma (SCCA-1) :. used for the detection, staging and monitoring response to therapy in patients with squamous cell carcinoma of the lung